{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:47:25Z","timestamp":1783021645100,"version":"3.54.6"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-024-02182-1","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:02:14Z","timestamp":1710288134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"Donal P.","family":"McLornan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3108-4035","authenticated-orcid":false,"given":"Tomasz","family":"Czerw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-3882","authenticated-orcid":false,"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ethell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-9697","authenticated-orcid":false,"given":"Nicola","family":"Polverelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Sockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-5328","authenticated-orcid":false,"given":"Greco","family":"Raffaella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"S\u00e1nchez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-3879","authenticated-orcid":false,"given":"Giorgia","family":"Battipaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-6156","authenticated-orcid":false,"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-6213","authenticated-orcid":false,"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5095","authenticated-orcid":false,"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"2182_CR1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/ajh.26962","volume":"98","author":"A Pardanani","year":"2023","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023;98:1097\u2013116.","journal-title":"Am J Hematol"},{"key":"2182_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev-pathmechdis-031521-042618","volume":"18","author":"P Valent","year":"2023","unstructured":"Valent P, Akin C, Sperr WR, Horny HP, Arock M, Metcalfe DD, et al. New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy. Annu Rev Pathol Mech Dis. 2023;18:361\u201386.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"2182_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2182_CR4","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2182_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603\u201325.","journal-title":"Leuk Res"},{"key":"2182_CR6","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","volume":"129","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420\u20137.","journal-title":"Blood"},{"key":"2182_CR7","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5:e646.","journal-title":"HemaSphere"},{"key":"2182_CR8","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727\u201336.","journal-title":"Blood"},{"key":"2182_CR9","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","volume":"6","author":"WR Sperr","year":"2019","unstructured":"Sperr WR, Kundi M, Alvarez-Twose I, Van Anrooij B, Oude Elberink JNG, Gorska A, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019;6:e638\u201349.","journal-title":"Lancet Haematol"},{"key":"2182_CR10","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021;27:2183\u201391.","journal-title":"Nat Med"},{"key":"2182_CR11","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","volume":"27","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27:2192\u20139.","journal-title":"Nat Med"},{"key":"2182_CR12","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of Midostaurin in advanced systemic mastocytosis. N. Engl J Med. 2016;374:2530\u201341.","journal-title":"N. Engl J Med"},{"key":"2182_CR13","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","volume":"22","author":"C Ustun","year":"2016","unstructured":"Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, et al. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transpl. 2016;22:1348\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2182_CR14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","volume":"10","author":"P Valent","year":"2022","unstructured":"Valent P, Hartmann K, Schwaab J, Alvarez-Twose I, Brockow K, Bonadonna P, et al. Personalized management strategies in mast cell disorders: ECNM-AIM User\u2019s guide for daily clinical practice. J Allergy Clin Immunol Pr. 2022;10:1999\u20132012.e6.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"2182_CR15","doi-asserted-by":"publisher","first-page":"15125","DOI":"10.3390\/ijms242015125","volume":"24","author":"P Valent","year":"2023","unstructured":"Valent P, Akin C, Arock M, Gleixner KV, Greinix H, Hermine O, et al. Antibody-based and cell therapies for advanced mastocytosis: established and novel concepts. Int J Mol Sci. 2023;24:15125.","journal-title":"Int J Mol Sci"},{"key":"2182_CR16","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","volume":"32","author":"C Ustun","year":"2014","unstructured":"Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32:3264\u201374.","journal-title":"J Clin Oncol"},{"key":"2182_CR17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","volume":"77","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77:1261\u201370.","journal-title":"Cancer Res"},{"key":"2182_CR18","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci. 1995;92:10560\u20134.","journal-title":"Proc Natl Acad Sci"},{"key":"2182_CR19","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.2019000932","volume":"135","author":"A Reiter","year":"2020","unstructured":"Reiter A, George TI, Gotlib J. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood. 2020;135:1365\u201376.","journal-title":"Blood"},{"key":"2182_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","volume":"13","author":"T Kristensen","year":"2011","unstructured":"Kristensen T, Vestergaard H, M\u00f8ller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011;13:180\u20138.","journal-title":"J Mol Diagn"},{"key":"2182_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","volume":"93","author":"P Erben","year":"2014","unstructured":"Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol. 2014;93:81\u20138.","journal-title":"Ann Hematol"},{"key":"2182_CR22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","volume":"29","author":"M Arock","year":"2015","unstructured":"Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29:1223\u201332.","journal-title":"Leukemia"},{"key":"2182_CR23","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.jaci.2022.04.004","volume":"149","author":"M Arock","year":"2022","unstructured":"Arock M, Hoermann G, Sotlar K, Hermine O, Sperr WR, Hartmann K, et al. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. J Allergy Clin Immunol. 2022;149:1855\u201365.","journal-title":"J Allergy Clin Immunol"},{"key":"2182_CR24","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.jaip.2022.05.034","volume":"10","author":"J Gotlib","year":"2022","unstructured":"Gotlib J, Schwaab J, Shomali W, George TI, Radia DH, Castells M, et al. Proposed European Competence Network on Mastocytosis\u2014American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis. J Allergy Clin Immunol Pr. 2022;10:2025\u20132038.e1.","journal-title":"J Allergy Clin Immunol Pr"},{"key":"2182_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bdq.2017.12.001","volume":"15","author":"S Stasik","year":"2018","unstructured":"Stasik S, Schuster C, Ortlepp C, Platzbecker U, Bornh\u00e4user M, Schetelig J, et al. An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants. Biomol Detect Quantif. 2018;15:6\u201312.","journal-title":"Biomol Detect Quantif"},{"key":"2182_CR26","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460\u20136.","journal-title":"Blood"},{"key":"2182_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","volume":"130","author":"M Jawhar","year":"2017","unstructured":"Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130:137\u201345.","journal-title":"Blood"},{"key":"2182_CR28","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","volume":"2","author":"A Pardanani","year":"2018","unstructured":"Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 2018;2:2964\u201372.","journal-title":"Blood Adv"},{"key":"2182_CR29","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","volume":"8","author":"JI Mu\u00f1oz-Gonz\u00e1lez","year":"2021","unstructured":"Mu\u00f1oz-Gonz\u00e1lez JI, \u00c1lvarez-Twose I, Jara-Acevedo M, Zanotti R, Perkins C, Jawhar M, et al. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematol. 2021;8:e194\u2013204.","journal-title":"Lancet Haematol"},{"key":"2182_CR30","doi-asserted-by":"publisher","first-page":"68950","DOI":"10.18632\/oncotarget.10711","volume":"8","author":"I Alvarez-Twose","year":"2017","unstructured":"Alvarez-Twose I, Matito A, Morgado JM, S\u00e1nchez-Mu\u00f1oz L, Jara-Acevedo M, Garc\u00eda-Montero A, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. 2017;8:68950\u201363.","journal-title":"Oncotarget"},{"key":"2182_CR31","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1200\/JCO.21.01849","volume":"40","author":"J L\u00fcbke","year":"2022","unstructured":"L\u00fcbke J, Schwaab J, Naumann N, Horny HP, Wei\u00df C, Metzgeroth G, et al. Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis. J Clin Oncol. 2022;40:1783\u201394.","journal-title":"J Clin Oncol"},{"key":"2182_CR32","doi-asserted-by":"publisher","first-page":"e000606","DOI":"10.1136\/esmoopen-2019-000606","volume":"4","author":"K Tzogani","year":"2019","unstructured":"Tzogani K, Yu Y, Meulendijks D, Herberts C, Hennik P, Verheijen R, et al. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis. ESMO Open. 2019;4:e000606.","journal-title":"ESMO Open"},{"key":"2182_CR33","unstructured":"FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/207997Orig1Orig2s000MedR.pdf."},{"key":"2182_CR34","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","volume":"36","author":"A Reiter","year":"2022","unstructured":"Reiter A, Gotlib J, \u00c1lvarez-Twose I, Radia DH, L\u00fcbke J, Bobbili PJ, et al. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia. 2022;36:2108\u201320.","journal-title":"Leukemia"},{"key":"2182_CR35","doi-asserted-by":"crossref","unstructured":"Gotlib J. Avapritinib in patients with Advanced Systemic Mastocytosis (AdvSM): Efficacy and safety analyses from the Phase 2 PATHFINDER study with 2\u2011year follow\u2011up. In. Available from: https:\/\/clml-soho2023.elsevierdigitaledition.com\/388\/index.html.","DOI":"10.1097\/01.HS9.0000970992.31848.76"},{"key":"2182_CR36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N. Engl J Med. 2017;377:454\u201364.","journal-title":"N. Engl J Med"},{"key":"2182_CR37","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00277-023-05180-y","volume":"102","author":"J L\u00fcbke","year":"2023","unstructured":"L\u00fcbke J, Naumann N, Metzgeroth G, Kreil S, Brand T, Horny HP, et al. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis. Ann Hematol. 2023;102:2077\u201385.","journal-title":"Ann Hematol"},{"key":"2182_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1034\/j.1600-0609.2003.00122.x","volume":"71","author":"A Wrzesie\u0144\u2010Ku\u015b","year":"2003","unstructured":"Wrzesie\u0144\u2010Ku\u015b A, Robak T, Lech\u2010Mara\u0144da E, Wierzbowska A, Dmoszy\u0144ska A, Kowal M, et al. A multicenter, open, non\u2010comparative, phase II study of the combination of cladribine (2\u2010chlorodeoxyadenosine), cytarabine, and G\u2010CSF as induction therapy in refractory acute myeloid leukemia \u2013 a report of the Polish Adult Leukemia Group (PALG). Eur J Haematol. 2003;71:155\u201362.","journal-title":"Eur J Haematol"},{"key":"2182_CR39","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/01.HS9.0000847064.38588.9b","volume":"6","author":"DJ DeAngelo","year":"2022","unstructured":"DeAngelo DJ, Pullarkat V, Piris-Villaespesa M, George TI, Patel JL, Ustun C, et al. P1049: A phase 2 study of Bezuclastinib (CGT9486), A novel, highly selective, potent KIT D816V, inhibitor in adults with advanced systemic mastocytosis (APEX): Methods, baseline data, and early insights. HemaSphere. 2022;6:939\u201340.","journal-title":"HemaSphere"},{"key":"2182_CR40","doi-asserted-by":"publisher","first-page":"6877","DOI":"10.1182\/blood-2022-167410","volume":"140","author":"DJ DeAngelo","year":"2022","unstructured":"DeAngelo DJ, Reiter A, George TI, Radia DH, Devlin M, Dimitrijevi\u0107 S, et al. AZURE: A phase 1\/2 study of BLU-263 as monotherapy and in combination with Azacitidine in PATIENTS WITH ADVANCED SYSTEMIC Mastocytosis. Blood. 2022;140:6877\u20138.","journal-title":"Blood"},{"key":"2182_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41409-023-01958-w","volume":"58","author":"I Yakoub-Agha","year":"2023","unstructured":"Yakoub-Agha I, Greco R, Onida F, De La C\u00e1mara R, Ciceri F, Corbacioglu S, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transpl. 2023;58:696\u2013700.","journal-title":"Bone Marrow Transpl"},{"key":"2182_CR42","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/JCO.19.00640","volume":"37","author":"M Jawhar","year":"2019","unstructured":"Jawhar M, Schwaab J, \u00c1lvarez-Twose I, Shoumariyeh K, Naumann N, L\u00fcbke J, et al. MARS: Mutation-adjusted risk score for advanced systemic mastocytosis. J Clin Oncol. 2019;37:2846\u201356.","journal-title":"J Clin Oncol"},{"key":"2182_CR43","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.3390\/ijms22052562","volume":"22","author":"N Naumann","year":"2021","unstructured":"Naumann N, L\u00fcbke J, Baumann S, Schwaab J, Hoffmann O, Kreil S, et al. Adverse prognostic impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis. Int J Mol Sci. 2021;22:2562.","journal-title":"Int J Mol Sci"},{"key":"2182_CR44","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s41375-018-0121-1","volume":"32","author":"Patnaik","year":"2018","unstructured":"Patnaik, Rangit Vallapureddy MM, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, et al. A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia. 2018;32:1850\u20136.","journal-title":"Leukemia"},{"key":"2182_CR45","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/path.2677","volume":"220","author":"K Sotlar","year":"2010","unstructured":"Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, B\u00fcltmann B, et al. Variable presence of KIT D816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010;220:586\u201395.","journal-title":"J Pathol"},{"key":"2182_CR46","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s41375-018-0346-z","volume":"33","author":"M Jawhar","year":"2019","unstructured":"Jawhar M, D\u00f6hner K, Kreil S, Schwaab J, Shoumariyeh K, Meggendorfer M, et al. KIT D816 mutated\/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia. 2019;33:1124\u201334.","journal-title":"Leukemia"},{"key":"2182_CR47","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","volume":"25","author":"P Valent","year":"2014","unstructured":"Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol. 2014;25:1691\u2013700.","journal-title":"Ann Oncol"},{"key":"2182_CR48","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/bloodadvances.2022008292","volume":"7","author":"VE Kennedy","year":"2023","unstructured":"Kennedy VE, Perkins C, Reiter A, Jawhar M, L\u00fcbke J, Kluin-Nelemans HC, et al. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry. Blood Adv. 2023;7:1713\u201324.","journal-title":"Blood Adv"},{"key":"2182_CR49","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1182\/blood-2023-185890","volume":"142","author":"M Heiblig","year":"2023","unstructured":"Heiblig M, Gourguechon C, Guilpain P, Livideanu CB, Barete S, Agopian J, et al. Prognostic characterization of advanced mastocytosis patients treated with Midostaurin according to diagnosis and mutation-adjusted risk score: a nation-wide Ceremast Study of 170 patients. Blood. 2023;142:1837.","journal-title":"Blood"},{"key":"2182_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-137413","volume":"136","author":"J Gotlib","year":"2020","unstructured":"Gotlib J, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, et al. Pure pathologic response is associated with improved overall survival in patients with advanced systemic mastocytosis receiving Avapritinib in the Phase I EXPLORER Study. Blood. 2020;136:37\u20138.","journal-title":"Blood"},{"key":"2182_CR51","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden JA, S\u00e1nchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, De La Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 2022;57:1217\u201339.","journal-title":"Bone Marrow Transpl"},{"key":"2182_CR52","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","volume":"26","author":"AS Kanate","year":"2020","unstructured":"Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transpl. 2020;26:1247\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2182_CR53","doi-asserted-by":"publisher","first-page":"103398","DOI":"10.1016\/j.retram.2023.103398","volume":"71","author":"P Sriskandarajah","year":"2023","unstructured":"Sriskandarajah P, McLornan DP, Oni C, Wilson A, Woodley C, Ciesielska M, et al. Advanced Systemic Mastocytosis with associated haematological neoplasm: treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant. Curr Res Transl Med. 2023;71:103398.","journal-title":"Curr Res Transl Med"},{"key":"2182_CR54","first-page":"355","volume":"13","author":"L Degenfeld-Schonburg","year":"2023","unstructured":"Degenfeld-Schonburg L, Gamperl S, Stefanzl G, Schruef AK, Sadovnik I, Bauer K, et al. Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V+ systemic mastocytosis: a preclinical study. Am J Cancer Res. 2023;13:355\u201378.","journal-title":"Am J Cancer Res"},{"key":"2182_CR55","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","volume":"39","author":"M\u2010T Krauth","year":"2009","unstructured":"Krauth M\u2010T, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E\u2010dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 2009;39:1711\u201320.","journal-title":"Clin Exp Allergy"},{"key":"2182_CR56","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1182\/bloodadvances.2022008038","volume":"6","author":"K Cavazos","year":"2022","unstructured":"Cavazos K, Eswaran S, Maidlow C, Keklik Karadag F, Idilman R, Idilman I, et al. Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis. Blood Adv. 2022;6:5630\u20133.","journal-title":"Blood Adv"},{"key":"2182_CR57","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/ejh.12720","volume":"96","author":"C Ustun","year":"2016","unstructured":"Ustun C, Smith A, Cayci Z, Courville EL, Corbacioglu S, Akin C, et al. Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno\u2010occlusive disease? Eur J Haematol. 2016;96:655\u20137.","journal-title":"Eur J Haematol"},{"key":"2182_CR58","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.1158\/1078-0432.CCR-05-1064","volume":"11","author":"WR Sperr","year":"2005","unstructured":"Sperr WR, Drach J, Hauswirth AW, Ackermann J, Mitterbauer M, Mitterbauer G, et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res. 2005;11:6787\u201392.","journal-title":"Clin Cancer Res"},{"key":"2182_CR59","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1111\/bjh.15980","volume":"186","author":"A Martynova","year":"2019","unstructured":"Martynova A, Nael A, O\u2019Neill C, Ramsingh G, Merchant A, Yaghmour B, et al. Aggressive systemic mastocytosis: midostaurin is safe, feasible and associated with durable response post\u2010haploidentical allogeneic stem cell transplant. Br J Haematol. 2019;186:e139\u2013e141. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15980.","journal-title":"Br J Haematol"},{"key":"2182_CR60","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/sj.bmt.1704627","volume":"34","author":"A Spyridonidis","year":"2004","unstructured":"Spyridonidis A, Thomas AK, Bertz H, Zeiser R, Schmitt-Gr\u00e4ff A, Lindemann A, et al. Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transpl. 2004;34:515\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2182_CR61","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/ejh.13528","volume":"106","author":"H H\u00e4gglund","year":"2021","unstructured":"H\u00e4gglund H, Yavuz AS, Dreimane A, Malm C, Sundin A, Sander B, et al. Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle. Eur J Haematol. 2021;106:290\u20133.","journal-title":"Eur J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02182-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02182-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02182-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T18:42:17Z","timestamp":1713897737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02182-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":61,"alternative-id":["2182"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02182-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"24 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There was no external funding associated with this consensus-based expert opinion paper. For each individual author, declarations of interest are as below: Donal P McLornan: Advisory boards and research funding from Novartis. Educational events on behalf of Novartis. Tomasz Czerw: No relevant disclosures. Gandhi Damaj: Travel expenses from Novartis and speakers bureau\/ advisory boards on behalf of Blueprint Medicines Corporation. Mark Ethell: No relevant disclosures. Carmelo Gurnari: No relevant disclosures. Juan Carlos Hern\u00e1ndez-Boluda: No relevant disclosures. Nicola Polverelli: No relevant disclosures. Juliana Schwaab: No relevant disclosures. Katja Sockel: Advisory boards and received lecture fees from Novartis, BMS\/Celgene and Blueprint Medicines Corporation. Raffaella Greco: Discloses speaking honoraria from Biotest, Pfizer, Medac, Neovii and Magenta. Francesco Onida: No relevant disclosures. Isabel S\u00e1nchez-Ortega: No relevant disclosures. Giorgia Battipaglia: No relevant disclosures. Chiara Elena: Advisory Boards for Cogent Biosciences, Blueprint Medicines Corporation, Istituto Gentili. Jason Gotlib: Incyte: Consultancy, Honoraria, Research Funding; Deciphera: Consultancy, Honoraria, Research Funding; PharmaEssentia: Consultancy, Honoraria, Research Funding; Blueprint Medicines Corporation: Consultancy, Honoraria, Research Funding; Kartos: Honoraria, Advisory committees, Research Funding; BMS: Research Funding; Abbvie: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Cogent Biosciences: Consultancy, Research Funding; Allakos: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding. Andreas Reiter: AbbVie: Consultancy, Honoraria, Research Funding; Blueprint Medicines Corporation: Consultancy, Honoraria, Research Funding; AOP Orphan Pharmaceuticals: Consultancy, Honoraria, Research Funding, Incyte Corporation: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; GSK: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding. Julien Rossignol: served on an advisory board for Blueprint Medicines Corporation; and has received research grants from Blueprint Medicines Corporation, BMS, and Novartis. Celalettin Ustun: Speaker Bureau honoraria: Takeda and Blueprint Medicines Corporation. Peter Valent: Project-Related: none. Project-Independent but Related to Mastocytosis in General: Ad-Board Honoraria: Novartis, Blueprint Medicines Corporation, Cogent. Ibrahim Yakoub-Agha: No relevant disclosures. Deepti H Radia: Clinical advisory board\/study steering group member (EXPLORER\/PATHFINDER) for Blueprint Medicines Corporation; a study steering committee member for Cogent Biosciences; and involved in educational events and advisory boards for Novartis. Author fees for Medscape cases. Royalties for Fast Facts: Systemic Mastocytosis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}